Storia della carriera di Denis G. Bosc
Precedenti posizioni note di Denis G. Bosc
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NERVGEN PHARMA CORP. | Corporate Officer/Principal | 30/05/2019 | 01/04/2020 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 17/01/2011 | 01/10/2012 |
| SQI DIAGNOSTICS INC. | Corporate Officer/Principal | 10/08/2009 | 01/08/2010 |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Corporate Officer/Principal | 01/01/2007 | 01/08/2008 |
Formazione di Denis G. Bosc
| University of Manitoba | Doctorate Degree |
Statistiche
Distribuzione geografica
| Canada | 5 |
| Regno Unito | 2 |
Posizioni
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SQI DIAGNOSTICS INC. | Health Technology |
| NERVGEN PHARMA CORP. | Health Technology |
| Aziende private | 2 |
|---|---|
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
- Borsa valori
- Insiders
- Denis G. Bosc
- Esperienza
